
  
    
      
        Introduction_NNP
        Genes_NNP of_IN the_DT 
        ERBB_NNP family_NN encode_NN receptor_NN tyrosine_NN kinases_NNS that_WDT mediate_VB cellular_JJ
        responses_NNS to_TO growth_VB signals_NNS ._. Somatic_NNP mutations_NNS in_IN the_DT tyrosine_NN kinase_NN domains_NNS of_IN two_CD 
        ERBB_NNP genes_NNS ,_, 
        epidermal_NN growth_NN factor_NN receptor_NN (_( EGFR_NNP )_) and_CC 
        HER_NNP 2_CD ,_, have_VBP been_VBN found_VBN in_IN a_DT proportion_NN of_IN lung_NN adenocarcinomas_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._.
        For_IN 
        EGFR_NNP ,_, mutations_NNS are_VBP associated_VBN with_IN sensitivity_NN to_TO the_DT small-molecule_JJ
        kinase_NN inhibitors_NNS gefitinib_NN (_( Iressa_NNP )_) [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN and_CC erlotinib_NN (_( Tarceva_NNP )_) [_NN 3_CD ]_NN ._.
        ERBB_NNP signaling_VBG pathways_NNS include_VBP downstream_JJ GTPases_NNP encoded_JJ by_IN 
        RAS_NNP genes_NNS ._. Some_DT 15_CD %_NN –_NN 30_CD %_NN of_IN lung_NN adenocarcinomas_NNS contain_VBP activating_VBG
        mutations_NNS in_IN the_DT 
        RAS_NNP family_NN member_NN 
        KRAS_NNP ._. These_DT mutations_NNS are_VBP most_RBS frequently_RB found_VBD in_IN codons_NNS 12_CD and_CC 13_CD in_IN
        exon_NN 2_CD [_NN 5_CD ,_, 6_CD ]_NN ,_, and_CC may_MD be_VB associated_VBN with_IN unfavorable_JJ outcomes_NNS [_NN 7_CD ]_NN ._. Interestingly_RB ,_, 
        EGFR_NNP and_CC 
        KRAS_NNP mutations_NNS are_VBP rarely_RB found_VBN in_IN the_DT same_JJ tumors_NNS ,_, suggesting_VBG that_IN they_PRP
        have_VBP functionally_RB equivalent_NN roles_NNS in_IN lung_NN tumorigenesis_NNS (_( [_NN 8_CD ]_NN ;_: M_NNP ._. Meyerson_NNP ,_, personal_JJ
        communication_NN )_) ._. Furthermore_RB ,_, 
        EGFR_NNP mutations_NNS are_VBP common_JJ in_IN tumors_NNS from_IN patients_NNS who_WP have_VBP smoked_VBD less_JJR
        than_IN 100_CD cigarettes_NNS in_IN their_PRP$ lifetimes_NNS (_(“ never_RB smokers_NNS” )_) [_NN 3_CD ]_NN ,_, while_IN 
        KRAS_NNP mutations_NNS more_RBR commonly_RB occur_VB in_IN individuals_NNS with_IN a_DT history_NN of_IN
        substantial_JJ cigarette_NN use_NN [_NN 9_CD ]_NN ._.
        We_PRP sought_VBD to_TO determine_VB whether_IN 
        KRAS_NNP mutations_NNS could_MD also_RB be_VB used_VBN to_TO predict_VB primary_JJ sensitivity_NN or_CC
        resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN ._. We_PRP systematically_RB evaluated_VBD 60_CD lung_NN adenocarcinomas_NNS
        from_IN patients_NNS with_IN known_VBN responses_NNS to_TO either_CC of_IN these_DT drugs_NNS for_IN the_DT presence_NN of_IN mutations_NNS
        in_IN 
        EGFR_NNP (_( exons_NNS 18_CD through_IN 21_CD )_) and_CC 
        KRAS_NNP 2_CD (_( exon_NN 2_LS )_) ._. Here_RB ,_, we_PRP show_VBP that_IN mutations_NNS in_IN 
        KRAS_NNP are_VBP associated_VBN with_IN primary_JJ resistance_NN to_TO single-agent_JJ gefitinib_NN or_CC
        erlotinib_NN ._. Our_PRP$ results_NNS suggest_VBP that_IN a_DT determination_NN of_IN mutational_NN status_NN for_IN both_DT 
        EGFR_NNP and_CC 
        KRAS_NNP may_MD help_VB define_VB which_WDT patients_NNS are_VBP likely_JJ to_TO benefit_VB from_IN receiving_VBG
        gefitinib_NN or_CC erlotinib_NN ._.
      
      
        Methods_NNP
        
          Tissue_NNP Procurement_NNP
          Tumor_NNP specimens_NNS were_VBD obtained_VBN through_IN protocols_NNS approved_VBN by_IN the_DT institutional_JJ review_NN
          board_NN of_IN Memorial_NNP Sloan-_NNP Kettering_NNP Cancer_NNP Center_NNP ,_, as_RB previously_RB described_VBD [_NN 3_CD ]_NN (_( see_VB
          Protocols_NNP S_NNP 1_CD –_NN S_NNP 3_LS )_) ._. Tumor_NNP material_NN ,_, obtained_VBN from_IN patients_NNS prior_RB to_TO kinase_NN inhibitor_NN
          treatment_NN for_IN lung_NN cancer_NN ,_, was_VBD collected_VBN retrospectively_RB for_IN patients_NNS on_IN gefitinib_NN ,_, who_WP
          received_VBD 250_CD mg_NN or_CC 500_CD mg_NN orally_RB once_RB daily_JJ (_(
          n_NN =_SYM 24_CD )_) ,_, and_CC prospectively_RB for_IN patients_NNS on_IN erlotinib_NN ,_, who_WP received_VBD 150_CD
          mg_NN orally_RB once_RB daily_JJ (_(
          n_NN =_SYM 36_CD )_) ._. The_DT latter_JJ cohort_NN of_IN patients_NNS was_VBD part_NN of_IN a_DT clinical_JJ trial_NN of_IN
          erlotinib_NN for_IN patients_NNS with_IN bronchioloalveolar_NN carcinoma_NN ._. The_DT analysis_NN presented_VBN here_RB
          includes_VBZ specimens_NNS we_PRP previously_RB reported_VBD on_IN (_(
          n_NN =_SYM 17_CD for_IN gefitinib_NN and_CC 
          n_NN =_SYM 17_CD for_IN erlotinib_NN )_) [_NN 3_CD ]_NN ._.
          All_DT specimens_NNS were_VBD reviewed_VBN by_IN a_DT single_JJ reference_NN pathologist_NN (_( M_NNP ._. F_NN ._. Z_NNP ._. )_) ._. Imaging_NNP
          studies_NNS were_VBD assessed_VBN by_IN a_DT single_JJ reference_NN radiologist_NN (_( R_NN ._. T_NN ._. H_NNP ._. )_) ,_, who_WP graded_JJ responses_NNS
          according_VBG to_TO Response_NNP Evaluation_NNP Criteria_NNP in_IN Solid_NNP Tumors_NNP (_( RECIST_NNP )_) [_NN 10_CD ]_NN ._. Both_DT observers_NNS
          were_VBD blinded_JJ to_TO patient_NN outcomes_NNS ._.
          Eight_CD of_IN nine_CD patients_NNS with_IN tumors_NNS sensitive_JJ to_TO gefitinib_NN had_VBD objective_NN partial_JJ
          responses_NNS as_IN defined_VBN by_IN RECIST_NNP ,_, i_NNP ._. e_SYM ._. ,_, at_IN least_JJS a_DT 30_CD %_NN decrease_NN in_IN the_DT sum_NN of_IN the_DT longest_JJS
          diameters_NNS of_IN target_NN lesions_NNS ,_, taking_VBG as_IN reference_NN the_DT sum_NN measured_VBN at_IN baseline_NN ._. The_DT ninth_JJ
          patient_NN had_VBD marked_VBN clinical_JJ improvement_NN ,_, as_IN ascertained_JJ by_IN two_CD independent_JJ reviewing_VBG
          physicians_NNS and_CC manifested_JJ by_IN lessened_JJ dyspnea_NN and_CC cancer-related_JJ pain_NN ._. However_RB ,_, this_DT
          individual_NN had_VBD radiographic_JJ lesions_NNS (_( pleural_NN and_CC bone_NN metastases_NNS )_) that_WDT were_VBD deemed_VBN
          nonmeasurable_JJ by_IN RECIST_NNP criteria_NNS ._. As_IN erlotinib-treated_JJ patients_NNS were_VBD all_DT in_IN a_DT clinical_JJ
          trial_NN ,_, all_DT had_VBN disease_NN measurable_JJ using_VBG RECIST_NNP guidelines_NNS ._. For_IN both_DT drugs_NNS in_IN this_DT study_NN ,_,
          tumors_NNS were_VBD considered_VBN refractory_JJ if_IN they_PRP did_VBD not_RB undergo_VB sufficient_JJ shrinkage_NN to_TO qualify_VB
          for_IN partial_JJ response_NN ._. This_DT definition_NN includes_VBZ patients_NNS whose_WP$ “ best_JJS overall_JJ response_NN” was_VBD
          either_CC progression_NN of_IN disease_NN (_(
          n_NN =_SYM 26_CD )_) or_CC stable_JJ disease_NN (_(
          n_NN =_SYM 12_CD )_) as_IN defined_VBN by_IN RECIST_NNP ._. No_DT patients_NNS had_VBD a_DT complete_JJ response_NN ._.
        
        
          Mutational_NNP Analyses_NNS of_IN EGFR_NNP and_CC KRAS_NNP in_IN Lung_NNP Tumors_NNP
          Genomic_NNP DNA_NNP was_VBD extracted_VBN from_IN tumors_NNS embedded_VBN in_IN paraffin_NN blocks_NNS ,_, except_IN for_IN tumor_NN
          109_CD T_NN ,_, which_WDT was_VBD a_DT fresh-frozen_JJ tumor_NN specimen_NN ._. Primers_NNP for_IN 
          EGFR_NNP analyses_NNS (_( exons_NNS 18_CD –_NN 21_CD )_) were_VBD as_IN published_VBN [_NN 3_CD ]_NN ._. For_IN 
          KRAS_NNP analyses_NNS ,_, the_DT following_VBG nested_JJ primer_NN sets_NNS for_IN exon_NN 2_CD were_VBD used_VBN :_:
          huKRAS_NN 2_CD ex_FW 2_CD F_NN ,_, 5_CD ′_NN -_: GAATGGTCCTGCACCAGTAA-_NNP 3_CD ′_NN ;_: huKRAS_NN 2_CD ex_FW 2_CD R_NN ,_, 5_CD ′_NN -_: GTGTGACATGTTCTAATATAGTCA-_NNP 3_CD ′_NN ;_:
          huKRAS_NN 2_CD ex_FW 2_CD Fint_NNP ,_, 5_CD ′_NN -_: GTCCTGCACCAGTAATATGC-_NNP 3_CD ′_NN ;_: and_CC huKRAS_NN 2_CD ex_FW 2_CD Rint_NNP ,_, 5_CD ′_NN -_:
          ATGTTCTAATATAGTCACATTTTC-_NNP 3_CD ′_NN ._.
          For_IN both_DT 
          EGFR_NNP and_CC 
          KRAS_NNP ,_, PCR_NNP was_VBD performed_VBN using_VBG the_DT HotStarTaq_NNP Master_NNP Mix_NNP Kit_NNP (_( Qiagen_NNP ,_,
          Valencia_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ,_, as_IN per_IN manufacturer_NN 's_POS instructions_NNS ._. Use_NN of_IN this_DT
          method_NN often_RB obviated_JJ the_DT need_NN for_IN nested_JJ PCR_NNP sets_NNS ._. All_DT sequencing_VBG reactions_NNS were_VBD
          performed_VBN in_IN both_DT forward_RB and_CC reverse_VB directions_NNS ,_, and_CC all_DT mutations_NNS were_VBD confirmed_VBN by_IN PCR_NNP
          amplification_NN of_IN an_DT independent_JJ DNA_NNP isolate_VB ._.
          In_IN 12_CD cases_NNS ,_, exon_NN 19_CD deletions_NNS were_VBD also_RB studied_VBN by_IN length_NN analysis_NN of_IN fluorescently_RB
          labeled_VBN PCR_NNP products_NNS on_IN a_DT capillary_JJ electrophoresis_NNS device_NN ,_, using_VBG the_DT following_JJ primers_NNS :_: 
          EGFR_NNP -_: Ex_NNP 19_CD -_: FWD_NNP 1_CD ,_, 5_CD ′_NN -_: GCACCATCTCACAATTGCCAGTTA-_NNP 3_CD ′_NN ,_, and_CC 
          EGFR_NNP -_: Ex_NNP 19_CD -_: REV_NNP 1_CD ,_, 5_CD ′_NN -_: Fam-_NNP AAAAGGTGGGCCTGAGGTTCA-_NNP 3_CD ′_NN ._. Using_VBG serial_NN
          dilutions_NNS of_IN DNA_NNP from_IN the_DT H_NNP 1650_CD non-small-cell_JJ lung_NN cancer_NN cell_NN line_NN (_( exon_NN 19_CD
          deletion-positive_JJ [_NN 11_CD ]_NN )_) ,_, this_DT assay_NN detects_NNS the_DT mutant_JJ allele_NN when_WRB H_NNP 1650_CD DNA_NNP comprises_VBZ 6_CD %_NN
          or_CC more_JJR of_IN the_DT total_JJ DNA_NNP tested_VBD ,_, compared_VBN to_TO a_DT sensitivity_NN of_IN 12_CD %_NN for_IN direct_JJ sequencing_VBG ._.
          These_DT same_JJ cases_NNS were_VBD also_RB screened_VBD for_IN the_DT exon_NN 21_CD L_NNP 858_CD R_NN mutation_NN by_IN a_DT PCR–restriction_NNP
          fragment_NN length_NN polymorphism_NN assay_NN ,_, based_VBN on_IN a_DT new_JJ Sau_NNP 96_CD I_PRP restriction_NN site_NN created_VBN by_IN the_DT
          L_NNP 858_CD R_NN mutation_NN (_( 2_CD ,_, 573_CD T_NN →_NN G_NNP )_) ._. The_DT Sau_NNP 96_CD I-_NNP digested_VBN fluorescently_RB labeled_VBN PCR_NNP products_NNS were_VBD
          analyzed_VBN by_IN capillary_JJ electrophoresis_NNS ,_, and_CC the_DT following_VBG primers_NNS were_VBD used_VBN :_: 
          EGFR_NNP -_: Ex_NNP 21_CD -_: FWD_NNP 1_CD ,_, 5_CD ′_NN -_: CCTCACAGCAGGGTCTTCTCTGT-_NNP 3_CD ′_NN ,_, and_CC 
          EGFR_NNP -_: Ex_NNP 21_CD -_: REV_NNP 1_CD ,_, 5_CD ′_NN -_: Fam-_NNP TCAGGAAAATGCTGGCTGACCTA-_NNP 3_CD ′_NN ._. Using_VBG serial_NN
          dilutions_NNS of_IN DNA_NNP from_IN the_DT H_NNP 1975_CD cell_NN line_NN (_( L_NNP 858_CD R-_NNP positive_JJ [_NN 11_CD ]_NN )_) ,_, this_DT assay_NN detects_NNS the_DT
          mutant_JJ allele_NN when_WRB H_NNP 1975_CD DNA_NNP comprises_VBZ 3_CD %_NN or_CC more_JJR of_IN the_DT total_JJ DNA_NNP tested_VBD ,_, compared_VBN to_TO a_DT
          sensitivity_NN of_IN 6_CD %_NN for_IN direct_JJ sequencing_VBG (_( Q_NNP ._. Pan_NNP ,_, W_NNP ._. Pao_NNP ,_, and_CC M_NNP ._. Ladanyi_NNP ,_, unpublished_JJ
          data_NNS )_) ._.
        
        
          Statistics_NNS
          Fisher_NNP 's_POS Exact_JJ Test_NNP was_VBD used_VBN to_TO calculate_VB 
          p-_NN values_NNS ,_, and_CC confidence_NN intervals_NNS were_VBD calculated_VBN using_VBG 
          Statistics_NNPS with_IN Confidence_NN software_NN [_NN 12_CD ]_NN ._.
        
      
      
        Results_NNS
        We_PRP identified_VBD 60_CD lung_NN adenocarcinomas_NNS from_IN individual_JJ patients_NNS with_IN tumors_NNS shown_VBN to_TO be_VB
        sensitive_JJ or_CC refractory_JJ to_TO single-agent_JJ gefitinib_NN or_CC erlotinib_NN and_CC evaluated_VBD these_DT tumors_NNS
        for_IN mutations_NNS in_IN 
        EGFR_NNP and_CC 
        KRAS_NNP ._. Collectively_RB ,_, nine_CD of_IN 38_CD (_( 24_CD %_NN )_) tumors_NNS refractory_JJ to_TO either_CC kinase_NN
        inhibitor_NN had_VBD 
        KRAS_NNP mutations_NNS ,_, while_IN zero_CD of_IN 21_CD (_( 0_CD %_NN )_) drug-sensitive_JJ tumors_NNS had_VBD such_JJ
        mutations_NNS (_(
        p_NN =_SYM 0_CD ._. 02_CD )_) (_( Table_NNP 1_LS )_) ._. The_DT 95_CD %_NN confidence_NN intervals_NNS (_( CIs_NNP )_) for_IN these_DT
        observations_NNS are_VBP 13_CD %_NN –_NN 39_CD %_NN and_CC 0_CD %_NN –_NN 16_CD %_NN ,_, respectively_RB ._. Conversely_RB ,_, 17_CD of_IN 22_CD (_( 77_CD %_NN )_) tumors_NNS
        sensitive_JJ to_TO either_CC kinase_NN inhibitor_NN had_VBD 
        EGFR_NNP mutations_NNS ,_, in_IN contrast_NN to_TO zero_CD of_IN 38_CD (_( 0_CD %_NN )_) drug-resistant_JJ tumors_NNS (_(
        p_NN =_SYM 6_CD ._. 8_CD ×_NN 10_CD
        −_NN 11_CD )_) ._. The_DT 95_CD %_NN CIs_NNP for_IN these_DT observed_VBN response_NN rates_NNS are_VBP 57_CD %_NN –_NN 90_CD %_NN and_CC
        0_CD %_NN –_NN 9_CD %_NN ,_, respectively_RB ._. All_DT 17_CD tumors_NNS with_IN 
        EGFR_NNP mutations_NNS responded_VBD to_TO gefitinib_NN or_CC erlotinib_NN ,_, while_IN all_DT nine_CD tumors_NNS
        with_IN 
        KRAS_NNP mutations_NNS did_VBD not_RB (_(
        p_NN =_SYM 3_CD ._. 2_CD ×_NN 10_CD
        −_NN 7_CD )_) ._.
        Correlation_NNP of_IN 
        EGFR_NNP and_CC 
        KRAS_NNP mutational_NN status_NN with_IN drug_NN and_CC treatment_NN response_NN is_VBZ detailed_VBN in_IN
        Table_NNP 1_CD ._. The_DT spectrum_NN of_IN 
        KRAS_NNP mutations_NNS is_VBZ shown_VBN in_IN Figure_NN 1_CD and_CC Table_NNP 2_CD ._. Results_NNS with_IN gefitinib_NN
        and_CC erlotinib_NN were_VBD similar_JJ overall_NN ._. However_RB ,_, the_DT incidence_NN of_IN 
        KRAS_NNP mutations_NNS in_IN the_DT patients_NNS treated_VBN with_IN erlotinib_NN was_VBD low_JJ ,_, probably_RB
        because_IN of_IN the_DT fact_NN that_IN all_DT patients_NNS treated_VBN with_IN this_DT drug_NN had_VBD bronchioloalveolar_NN
        carcinoma_NN ,_, which_WDT rarely_RB has_VBZ 
        RAS_NNP mutations_NNS [_NN 13_CD ]_NN ._. Alternatively_RB ,_, our_PRP$ analyses_NNS involving_VBG only_RB exon_NN 2_CD of_IN 
        KRAS_NNP 2_CD may_MD have_VB missed_VBN some_DT 
        RAS_NNP mutations_NNS ._. However_RB ,_, in_IN our_PRP$ analysis_NN of_IN the_DT exonic_JJ regions_NNS encoding_VBG
        the_DT first_JJ 100_CD amino_JJ acids_NNS of_IN 
        KRAS_NNP in_IN 110_CD surgically_RB resected_JJ early-stage_JJ non-small-cell_JJ lung_NN cancers_NNS ,_,
        we_PRP have_VBP found_VBN 18_CD mutations_NNS ,_, and_CC all_DT were_VBD in_IN either_DT codon_NN 12_CD or_CC codon_NN 13_CD ,_, encoded_JJ by_IN exon_NN 2_CD
        (_( W_NNP ._. Pao_NNP ,_, R_NN ._. Wilson_NNP ,_, H_NNP ._. Varmus_NNP ,_, unpublished_JJ data_NNS )_) ._. Another_DT possibility_NN is_VBZ that_IN the_DT
        erlotinib-treated_JJ tumors_NNS have_VBP mutations_NNS in_IN other_JJ 
        RAS_NNP genes_NNS ,_, since_IN a_DT minority_NN of_IN 
        RAS_NNP mutations_NNS in_IN lung_NN cancer_NN have_VBP been_VBN reported_VBN to_TO occur_VB in_IN 
        N-_NNP or_CC 
        HRAS_NNP [_NN 5_CD ,_, 6_CD ]_NN ._.
      
      
        Discussion_NNP
        These_DT results_NNS have_VBP important_JJ clinical_JJ implications_NNS ._. First_LS ,_, they_PRP extend_VBP previous_JJ data_NNS
        from_IN our_PRP$ group_NN and_CC others_NNS showing_VBG that_IN lung_NN adenocarcinomas_NNS containing_VBG 
        EGFR_NNP mutations_NNS are_VBP associated_VBN with_IN sensitivity_NN to_TO gefitinib_NN or_CC erlotinib_NN
        (_( 17_CD of_IN 17_CD in_IN this_DT series_NN ;_: 100_CD %_NN observed_VBD response_NN rate_NN ;_: 95_CD %_NN CI_NNP ,_, 82_CD %_NN –_NN 100_CD %_NN )_) ._. Second_JJ ,_, these_DT
        data_NNS show_VBP that_IN tumors_NNS with_IN 
        KRAS_NNP exon_NN 2_CD mutations_NNS (_(
        n_NN =_SYM 9_CD )_) are_VBP associated_VBN with_IN a_DT lack_NN of_IN response_NN to_TO these_DT kinase_NN inhibitors_NNS
        (_( 0_CD %_NN observed_VBD response_NN rate_NN ;_: 95_CD %_NN CI_NNP ,_, 0_CD %_NN –_NN 30_CD %_NN )_) ._. Third_NNP ,_, no_DT drug-sensitive_JJ tumors_NNS had_VBD 
        KRAS_NNP exon_NN 2_CD mutations_NNS (_(
        n_NN =_SYM 21_CD )_) ._. Whether_IN 
        KRAS_NNP mutational_NN status_NN can_MD be_VB used_VBN to_TO predict_VB responses_NNS to_TO gefitinib_NN or_CC
        erlotinib_NN in_IN patients_NNS whose_WP$ tumors_NNS have_VBP wild-type_JJ 
        EGFR_NNP sequence_NN is_VBZ still_RB under_IN investigation_NN :_: our_PRP$ analysis_NN comparing_VBG
        response_NN rates_NNS for_IN tumors_NNS with_IN neither_DT 
        EGFR_NNP nor_CC 
        KRAS_NNP mutations_NNS versus_CC tumors_NNS with_IN wild-type_JJ 
        EGFR_NNP but_CC mutated_VBN 
        KRAS_NNP does_VBZ not_RB reach_VB statistical_JJ significance_NN (_( five_CD of_IN 22_CD versus_CC zero_CD of_IN
        nine_CD ;_: 
        p_NN =_SYM 0_CD ._. 29_CD )_) ._. Nevertheless_RB ,_, these_DT findings_NNS suggest_VBP that_IN patients_NNS whose_WP$ lung_NN
        adenocarcinomas_NNS have_VBP 
        KRAS_NNP mutations_NNS will_MD not_RB experience_VB significant_JJ tumor_NN regression_NN with_IN
        either_DT drug_NN ._.
        The_DT incidence_NN of_IN 
        EGFR_NNP mutations_NNS in_IN tumors_NNS responsive_JJ to_TO EGFR_NNP kinase_NN inhibitors_NNS has_VBZ varied_VBN
        from_IN 71_CD %_NN to_TO 100_CD %_NN (_( [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN and_CC this_DT paper_NN )_) ._. Thus_RB ,_, at_IN this_DT point_NN ,_, patients_NNS whose_WP$ tumors_NNS test_VBP
        negative_JJ for_IN 
        EGFR_NNP mutations_NNS should_MD not_RB necessarily_RB be_VB precluded_VBN from_IN treatment_NN with_IN
        either_DT gefitinib_NN or_CC erlotinib_NN ._. Data_NNP presented_VBD here_RB suggest_VBP that_IN clinical_JJ decisions_NNS
        regarding_VBG the_DT use_NN of_IN these_DT agents_NNS in_IN patients_NNS with_IN lung_NN adenocarcinomas_NNS might_MD be_VB improved_VBN
        in_IN the_DT future_NN by_IN pre-treatment_JJ mutational_NN profiling_VBG of_IN both_DT 
        EGFR_NNP and_CC 
        KRAS_NNP ._. These_DT findings_NNS warrant_VBP validation_NN in_IN large_JJ prospective_JJ trials_NNS
        using_VBG standardized_JJ mutation_NN detection_NN techniques_NNS ._.
        
          Supporting_VBG Information_NNP
        
        
          Accession_NNP Numbers_NNPS
          The_DT LocusLink_NNP (_( http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN LocusLink_NNP /_NN )_) accession_NN number_NN for_IN the_DT 
          KRAS_NNP 2_CD sequence_NN discussed_VBN in_IN this_DT paper_NN is_VBZ 3845_CD ;_: the_DT GenBank_NNP
          (_( http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN Genbank_NNP /_NN )_) accession_NN number_NN for_IN the_DT 
          KRAS_NNP 2_CD sequence_NN discussed_VBN in_IN this_DT paper_NN is_VBZ NT_NNP __NN 009714_CD ._. 16_CD ._.
        
      
    
  
